Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FGFR2 mutation
i
Other names:
FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2263
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
FGFR2 N549K (7)
FGFR2 rearrangement (7)
FGFR2 P253R (3)
FGFR2 K310R (2)
FGFR2 translocation (2)
ARID1A K1238fs + FGFR2 R210Q (1)
BAP1 mutation + FGFR2 rearrangement (1)
FDFT1 rearrangement + FGFR2 rearrangement (1)
FGFR2 A391E (1)
FGFR2 B252W (1)
FGFR2 C382R (1)
FGFR2 E250G (1)
FGFR2 E565A (1)
FGFR2 E565G (1)
FGFR2 E565K (1)
FGFR2 F276C (1)
FGFR2 M540_I541insMM (1)
FGFR2 N549D (1)
FGFR2 N549H (1)
FGFR2 N549T (1)
FGFR2 N550K (1)
FGFR2 S252W (1)
FGFR2 V564F (1)
FGFR2 V564I (1)
FGFR2 V564L (1)
FGFR2 Y375C (1)
FGFR2 Y376C (1)
PIK3CA mutation + FGFR2 rearrangement (1)
PIK3CB mutation + FGFR2 rearrangement (1)
PIK3R1 mutation + FGFR2 rearrangement (1)
TP53 mutation + FGFR2 rearrangement (1)
FGFR2 C383R (0)
FGFR2 K660N (0)
FGFR2 W290C (0)
FGFR2 wild-type (0)
FGFR2 N549K (7)
FGFR2 rearrangement (7)
FGFR2 P253R (3)
FGFR2 K310R (2)
FGFR2 translocation (2)
ARID1A K1238fs + FGFR2 R210Q (1)
BAP1 mutation + FGFR2 rearrangement (1)
FDFT1 rearrangement + FGFR2 rearrangement (1)
FGFR2 A391E (1)
FGFR2 B252W (1)
FGFR2 C382R (1)
FGFR2 E250G (1)
FGFR2 E565A (1)
FGFR2 E565G (1)
FGFR2 E565K (1)
FGFR2 F276C (1)
FGFR2 M540_I541insMM (1)
FGFR2 N549D (1)
FGFR2 N549H (1)
FGFR2 N549T (1)
FGFR2 N550K (1)
FGFR2 S252W (1)
FGFR2 V564F (1)
FGFR2 V564I (1)
FGFR2 V564L (1)
FGFR2 Y375C (1)
FGFR2 Y376C (1)
PIK3CA mutation + FGFR2 rearrangement (1)
PIK3CB mutation + FGFR2 rearrangement (1)
PIK3R1 mutation + FGFR2 rearrangement (1)
TP53 mutation + FGFR2 rearrangement (1)
FGFR2 C383R (0)
FGFR2 K660N (0)
FGFR2 W290C (0)
FGFR2 wild-type (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
FGFR2 mutation
Urothelial Cancer
FGFR2 mutation
Urothelial Cancer
erdafitinib
Sensitive: A1 - Approval
erdafitinib
Sensitive
:
A1
erdafitinib
Sensitive: A1 - Approval
erdafitinib
Sensitive
:
A1
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
KIN-3248
Sensitive: B - Late Trials
KIN-3248
Sensitive
:
B
KIN-3248
Sensitive: B - Late Trials
KIN-3248
Sensitive
:
B
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGFR2 mutation
Gastric Cancer
FGFR2 mutation
Gastric Cancer
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGFR2 mutation
Solid Tumor
FGFR2 mutation
Solid Tumor
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGFR2 mutation
Bladder Cancer
FGFR2 mutation
Bladder Cancer
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
infigratinib
Sensitive: C2 – Inclusion Criteria
infigratinib
Sensitive
:
C2
infigratinib
Sensitive: C2 – Inclusion Criteria
infigratinib
Sensitive
:
C2
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
ARQ 087
Sensitive: C2 – Inclusion Criteria
ARQ 087
Sensitive
:
C2
ARQ 087
Sensitive: C2 – Inclusion Criteria
ARQ 087
Sensitive
:
C2
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
futibatinib
Sensitive: C2 – Inclusion Criteria
futibatinib
Sensitive
:
C2
futibatinib
Sensitive: C2 – Inclusion Criteria
futibatinib
Sensitive
:
C2
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
TT-00420
Sensitive
:
C2
TT-00420
Sensitive: C2 – Inclusion Criteria
TT-00420
Sensitive
:
C2
FGFR2 mutation
Solid Tumor
FGFR2 mutation
Solid Tumor
TT-00420
Sensitive: C2 – Inclusion Criteria
TT-00420
Sensitive
:
C2
TT-00420
Sensitive: C2 – Inclusion Criteria
TT-00420
Sensitive
:
C2
FGFR2 mutation
Non Small Cell Lung Cancer
FGFR2 mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
FGFR2 mutation
Non Small Cell Lung Cancer
FGFR2 mutation
Non Small Cell Lung Cancer
nintedanib
Sensitive: C3 – Early Trials
nintedanib
Sensitive
:
C3
nintedanib
Sensitive: C3 – Early Trials
nintedanib
Sensitive
:
C3
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
pemigatinib
Sensitive: C3 – Early Trials
pemigatinib
Sensitive
:
C3
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
FGFR2 inhibitor
Resistant: C3 – Early Trials
FGFR2 inhibitor
Resistant
:
C3
FGFR2 inhibitor
Resistant: C3 – Early Trials
FGFR2 inhibitor
Resistant
:
C3
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
Debio 1347
Sensitive: C3 – Early Trials
Debio 1347
Sensitive
:
C3
Debio 1347
Sensitive: C3 – Early Trials
Debio 1347
Sensitive
:
C3
FGFR2 mutation
Melanoma
FGFR2 mutation
Melanoma
PD1 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor
Sensitive
:
C3
PD1 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor
Sensitive
:
C3
FGFR2 mutation
Melanoma
FGFR2 mutation
Melanoma
CTLA4 inhibitor
Sensitive: C3 – Early Trials
CTLA4 inhibitor
Sensitive
:
C3
CTLA4 inhibitor
Sensitive: C3 – Early Trials
CTLA4 inhibitor
Sensitive
:
C3
FGFR2 mutation
Melanoma
FGFR2 mutation
Melanoma
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 inhibitor
Sensitive
:
C3
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 inhibitor
Sensitive
:
C3
FGFR2 mutation
Urothelial Cancer
FGFR2 mutation
Urothelial Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
FGFR2 mutation
Solid Tumor
FGFR2 mutation
Solid Tumor
futibatinib
Sensitive: C3 – Early Trials
futibatinib
Sensitive
:
C3
futibatinib
Sensitive: C3 – Early Trials
futibatinib
Sensitive
:
C3
FGFR2 mutation
Solid Tumor
FGFR2 mutation
Solid Tumor
CPL304110
Sensitive: D – Preclinical
CPL304110
Sensitive
:
D
CPL304110
Sensitive: D – Preclinical
CPL304110
Sensitive
:
D
FGFR2 mutation
Multiple Myeloma
FGFR2 mutation
Multiple Myeloma
infigratinib
Sensitive: D – Preclinical
infigratinib
Sensitive
:
D
infigratinib
Sensitive: D – Preclinical
infigratinib
Sensitive
:
D
FGFR2 mutation
Endometrial Cancer
FGFR2 mutation
Endometrial Cancer
infigratinib
Sensitive: D – Preclinical
infigratinib
Sensitive
:
D
infigratinib
Sensitive: D – Preclinical
infigratinib
Sensitive
:
D
FGFR2 mutation
Endometrial Cancer
FGFR2 mutation
Endometrial Cancer
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
FGFR2 mutation
Endometrial Cancer
FGFR2 mutation
Endometrial Cancer
TKI258
Sensitive: D – Preclinical
TKI258
Sensitive
:
D
TKI258
Sensitive: D – Preclinical
TKI258
Sensitive
:
D
FGFR2 mutation
Estrogen Receptor Positive Breast Cancer
FGFR2 mutation
Estrogen Receptor Positive Breast Cancer
fulvestrant
Resistant: D – Preclinical
fulvestrant
Resistant
:
D
fulvestrant
Resistant: D – Preclinical
fulvestrant
Resistant
:
D
FGFR2 mutation
Estrogen Receptor Positive Breast Cancer
FGFR2 mutation
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: D – Preclinical
palbociclib
Resistant
:
D
palbociclib
Resistant: D – Preclinical
palbociclib
Resistant
:
D
FGFR2 mutation
Solid Tumor
FGFR2 mutation
Solid Tumor
eFT226
Sensitive: D – Preclinical
eFT226
Sensitive
:
D
eFT226
Sensitive: D – Preclinical
eFT226
Sensitive
:
D
FGFR2 mutation
Gastric Cancer
FGFR2 mutation
Gastric Cancer
KIN-3248
Sensitive: D – Preclinical
KIN-3248
Sensitive
:
D
KIN-3248
Sensitive: D – Preclinical
KIN-3248
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login